Corient Private Wealth
REGN icon

Corient Private Wealth’s Regeneron Pharmaceuticals REGN Stock Holding History

Corient Private Wealth’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$13.9M Sell
18,073
-21,536
-54% -$16.5M 0.02% 504
2025
Q4 		$25.2M Buy
39,609
+22,237
+128% +$15.1M 0.02% 510
2025
Q3 		$9.77M Buy
17,372
+174
+1% +$98.4K 0.02% 525
2025
Q2 		$9.03M Sell
17,198
-4,688
-21% -$2.62M 0.01% 544
2025
Q1 		$13.9M Sell
21,886
-998
-4% -$686K 0.02% 450
2024
Q4 		$16.3M Sell
22,884
-4,349
-16% -$3.65M 0.03% 425
2024
Q3 		$28.6M Buy
27,233
+4,992
+22% +$5.56M 0.04% 350
2024
Q2 		$23.4M Sell
22,241
-12,188
-35% -$11.8M 0.04% 360
2024
Q1 		$33.1M Buy
34,429
+868
+3% +$825K 0.06% 292
2023
Q4 		$29.5M Buy
33,561
+2,537
+8% +$2.09M 0.05% 317
2023
Q3 		$25.5M Buy
31,024
+823
+3% +$647K 0.06% 299
2023
Q2 		$21.7M Sell
30,201
-980
-3% -$756K 0.05% 316
2023
Q1 		$25.6M Buy
31,181
+16,479
+112% +$12.4M 0.07% 268
2022
Q4 		$10.6M Buy
+14,702
New +$10.8M 0.04% 360

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Corient Private Wealth's REGN Position: Q1 2026 in Review

Corient Private Wealth reduced its Regeneron Pharmaceuticals (REGN) stake by 54% in Q1 2026, selling an estimated $16.5M and leaving 18,073 shares worth $13.9M. The position accounts for 0.02% of the portfolio, ranked #504.

Corient Private Wealth first reported a position in REGN in Q4 2022 and has held it in 14 quarters since. The position peaked at $33.1M in Q1 2024. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Corient Private Wealth held 18,073 shares of Regeneron Pharmaceuticals worth $13.9M as of Q1 2026.
  • Corient Private Wealth sold 21,536 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $16.5M.
  • Regeneron Pharmaceuticals made up 0.02% of Corient Private Wealth's portfolio in Q1 2026, its #504 holding.
  • Corient Private Wealth first reported a position in Regeneron Pharmaceuticals in Q4 2022 and has held it in 14 quarters since.
  • Corient Private Wealth's Regeneron Pharmaceuticals position peaked at $33.1M in Q1 2024.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Corient Private Wealth's 13F filing for Q1 2026, filed 15 May 2026.